Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198321 | 0.86 | MAPK1 (0.38) | SCN9AMAPK1RORCS1PR1ACACB | |
| SCHEMBL10198424 | 0.82 | S1PR1 (0.41) | SCN9AMAPK1RORCS1PR1S1PR5 | |
| SCHEMBL365394 | 0.82 | S1PR1 (0.41) | SCN9AMAPK1RORCS1PR1S1PR5 | |
| SCHEMBL364997 | 0.82 | S1PR1 (0.41) | SCN9AMAPK1RORCS1PR1S1PR5 | |
| SCHEMBL16175138 | 0.81 | MAPK1 (0.40) | SCN9AMAPK1RORCLMNACYP2C9 | |
| SCHEMBL9379161 | 0.81 | S1PR1 (0.37) | SCN9ARORCS1PR1S1PR5S1PR3 | |
| SCHEMBL10198322 | 0.80 | MAPK1 (0.36) | SCN9AMAPK1RORCLMNACYP2C9 | |
| SCHEMBL15599222 | 0.79 | S1PR1 (0.38) | SCN9ARORCS1PR1S1PR5S1PR3 | |
| SCHEMBL365208 | 0.79 | SCN9A (0.47) | SCN9ACYP2C9SCN5A | |
| SCHEMBL17627108 | 0.79 | RORC (0.41) | SCN9ARORCS1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203572-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3854782-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3436432-B1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3436432-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2870138-B1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007877-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007877-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | BRIX1, SNRPD2, RDX | SCN9A 1104/4885MAPK1 4438/4885RORC 2547/4885 |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, P2RX3 | SCN9A 501/4885MAPK1 4603/4885RORC 2728/4885 |
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 20/4885MAPK1 222/4885RORC 3411/4885 |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SCN9A 1549/4885MAPK1 4419/4885RORC 2633/4885 |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, RRM1 | SCN9A 1549/4885MAPK1 4419/4885RORC 2633/4885 |
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885MAPK1 4455/4885RORC 2555/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 25/4885MAPK1 147/4885RORC 2944/4885 |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885MAPK1 4455/4885RORC 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.